Follow The Filings

Avidity Partners Management LP David Witzke

Dallas, TX 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $624M
  • 45 holdings
  • 2026 Q2
  • +41.2% QoQ
  • Top 5 70.9%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 45 holdings

Top 5 70.9%, top 10 81.9%

  1. DNTH, Dianthus Therapeutics 32.8%
  2. CGON, CG Oncology 15.9%
  3. ORKA, Oruka Therapeutics 11.6%
  4. JBIO, Jade Biosciences 6.1%
  5. ELVN, Enliven Therapeutics 4.5%
  6. CATX, Perspective Therapeutics 3.4%
  7. AKTS, Aktis Oncology 2.5%
  8. PVLA 1.7%
  9. MOBI, Mobia Medical 1.7%
  10. RGEN, Repligen 1.7%
  11. Immunic 1.6%
  12. Senseonics 1.5%
  13. Other 15.0%

AUM over time

2026 Q2 $624M +41.2% QoQ
2021 Q3: $4.5B 2021 Q3: $4.5B
Q3 2021
2021 Q4: $4.7B, +4.5% QoQ 2021 Q4: $4.7B, +4.5% QoQ
Q4
2022 Q1: $4.8B, +1.9% QoQ 2022 Q1: $4.8B, +1.9% QoQ
Q1 2022
2022 Q2: $4.4B, −9.3% QoQ 2022 Q2: $4.4B, −9.3% QoQ
Q2
2022 Q3: $4.9B, +12.9% QoQ 2022 Q3: $4.9B, +12.9% QoQ
Q3
2022 Q4: $4.6B, −6.2% QoQ 2022 Q4: $4.6B, −6.2% QoQ
Q4
2023 Q1: $3B, −34.7% QoQ 2023 Q1: $3B, −34.7% QoQ
Q1 2023
2023 Q2: $2.9B, −5.0% QoQ 2023 Q2: $2.9B, −5.0% QoQ
Q2
2023 Q3: $2.5B, −13.3% QoQ 2023 Q3: $2.5B, −13.3% QoQ
Q3
2023 Q4: $2.7B, +10.5% QoQ 2023 Q4: $2.7B, +10.5% QoQ
Q4
2024 Q1: $3.1B, +13.0% QoQ 2024 Q1: $3.1B, +13.0% QoQ
Q1 2024
2024 Q2: $2.4B, −24.1% QoQ 2024 Q2: $2.4B, −24.1% QoQ
Q2
2024 Q3: $2B, −16.7% QoQ 2024 Q3: $2B, −16.7% QoQ
Q3
2024 Q4: $1B, −48.1% QoQ 2024 Q4: $1B, −48.1% QoQ
Q4
2025 Q1: $525M, −48.4% QoQ 2025 Q1: $525M, −48.4% QoQ
Q1 2025
2025 Q2: $502M, −4.4% QoQ 2025 Q2: $502M, −4.4% QoQ
Q2
2025 Q3: $439M, −12.5% QoQ 2025 Q3: $439M, −12.5% QoQ
Q3
2025 Q4: $347M, −21.0% QoQ 2025 Q4: $347M, −21.0% QoQ
Q4
2026 Q1: $442M, +27.4% QoQ 2026 Q1: $442M, +27.4% QoQ
Q1 2026
2026 Q2: $624M, +41.2% QoQ 2026 Q2: $624M, +41.2% QoQ
Q2

Book

2025 Q4 2025 Q3, filed 13 Feb, long equity only

Download CSV Download Excel All activity
DNTH, Dianthus Therapeutics 25.01%, was 28.70% Reduce −34.3% 2,104,184 $41.21 $87M −1,100,000 −$39M
CGON, CG Oncology 17.64% Reduce −8.0% 1,472,699 $41.52 $61M −128,200 −$3.3M
JBIO, Jade Biosciences 6.23%, was 2.21% Add +24.3% 1,400,708 $15.43 $22M +273,522 +$12M
ORKA, Oruka Therapeutics 5.77% Hold 660,424 $30.31 $20M — —
TEVA, Teva Pharmaceutical Industries 3.76% Reduce −18.2% 417,300 $31.21 $13M −92,700 +$2.7M
BSX, Boston Scientific 3.15%, was 3.65% Reduce −30.3% 114,500 $95.35 $11M −49,800 −$5.1M
MDT, Medtronic 2.98%, was 4.13% Reduce −43.5% 107,600 $96.06 $10M −83,000 −$7.8M
CATX, Perspective Therapeutics 2.55%, was 2.34% Add +7.2% 3,210,733 $2.75 $8.8M +216,700 −$1.4M
ALNY, Alnylam Pharmaceuticals 2.41% New 21,000 $397.65 $8.4M +21,000 +$8.4M
RGEN, Repligen 2.38%, was 0.71% Add +115.9% 50,300 $163.86 $8.2M +27,000 +$5.1M
CNTX, Context Therapeutics 2.33% Reduce −38.7% 5,504,855 $1.47 $8.1M −3,477,000 −$609K
MCK, McKesson 2.25%, was 1.02% Add +64.1% 9,520 $820.29 $7.8M +3,720 +$3.3M
ICLR, Icon 1.74% New 33,100 $182.22 $6M +33,100 +$6M
A, Agilent Technologies 1.63% New 41,500 $136.07 $5.6M +41,500 +$5.6M
PFE, Pfizer 1.46%, was 2.12% Reduce −44.4% 203,600 $24.90 $5.1M −162,800 −$4.3M
CNC, Centene 1.42% New 119,400 $41.15 $4.9M +119,400 +$4.9M
KVUE, Kenvue 1.16% Reduce −12.2% 232,800 $17.25 $4M −32,400 −$288K
DHR, Danaher 1.12%, was 2.47% Reduce −68.9% 17,000 $228.92 $3.9M −37,700 −$7M
TMO, Thermo Fisher Scientific 1.12%, was 2.09% Reduce −64.6% 6,700 $579.45 $3.9M −12,200 −$5.3M
NVO, Novo Nordisk 0.99% New 67,300 $50.88 $3.4M +67,300 +$3.4M
PHAT, Phathom Pharmaceuticals 0.99% Reduce −32.7% 206,076 $16.59 $3.4M −99,924 −$183K
EHC, Encompass Health 0.97%, was 1.21% Reduce −24.6% 31,600 $106.14 $3.4M −10,300 −$2M
CI, Cigna 0.92%, was 1.09% Reduce −30.1% 11,600 $275.23 $3.2M −5,000 −$1.6M
COR, Cencora 0.92%, was 1.35% Reduce −50.5% 9,400 $337.75 $3.2M −9,600 −$2.8M
INSM, Insmed 0.89%, was 0.38% Add +52.6% 17,700 $174.04 $3.1M +6,100 +$1.4M
WAT, Waters 0.89% New 8,100 $379.83 $3.1M +8,100 +$3.1M
ACAD, Acadia Pharmaceuticals 0.82% Reduce −25.8% 106,900 $26.71 $2.9M −37,100 −$218K
GMAB, Genmab A/s 0.82%, was 1.73% Reduce −62.9% 92,000 $30.80 $2.8M −156,100 −$4.8M
NTRA, Natera 0.78%, was 2.58% Reduce −83.2% 11,800 $229.09 $2.7M −58,600 −$8.6M
IMUX, Immunic 0.72% Hold 4,699,411 $0.5337 $2.5M — —
ACHC 0.69% New 169,000 $14.19 $2.4M +169,000 +$2.4M
ITGR, Integer 0.67% New 29,800 $78.43 $2.3M +29,800 +$2.3M
ELVN, Enliven Therapeutics 0.62% Hold 140,300 $15.40 $2.2M — —
PVLA 0.58% New 19,300 $104.67 $2M +19,300 +$2M
HQY, Healthequity 0.45%, was 0.55% Reduce −33.2% 16,900 $91.61 $1.5M −8,400 −$849K
SCYX, Scynexis 0.38%, was 0.59% Reduce −37.9% 2,081,660 $0.6324 $1.3M −1,268,868 −$1.3M
IQV, IQVIA 0.29% New 4,400 $225.41 $992K +4,400 +$992K
KPTI, Karyopharm Therapeutics 0.29% Hold 134,566 $7.36 $990K — —
CORT, Corcept Therapeutics 0.22% New 22,000 $34.80 $766K +22,000 +$766K

Exits / last held

Gone since 2025 Q3, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
BMY, Bristol Myers Squibb 2.64% Exit 0 $45.10 $12M −257,600 −$12M
Metsera 1.67% Exit 0 $52.33 $7.4M −140,500 −$7.4M
UNH, UnitedHealth Group 1.40% Exit 0 $345.28 $6.1M −17,800 −$6.1M
ARVN, Arvinas 1.35% Exit 0 $8.52 $6M −698,363 −$6M
JNJ, Johnson & Johnson 1.13% Exit 0 $185.41 $5M −26,800 −$5M
ABBV, AbbVie 1.04% Exit 0 $231.52 $4.6M −19,800 −$4.6M
CARL, Carlsmed 0.98% Exit 0 $13.39 $4.3M −321,912 −$4.3M
ARQT, Arcutis Biotherapeutics 0.92% Exit 0 $18.85 $4M −214,400 −$4M
Exact Sciences 0.92% Exit 0 $54.71 $4M −73,600 −$4M
ASND, Ascendis Pharma A/s 0.66% Exit 0 $198.83 $2.9M −14,500 −$2.9M
BEAM, Beam Therapeutics 0.62% Exit 0 $24.27 $2.7M −112,000 −$2.7M
WVE, Wave Life Sciences 0.50% Exit 0 $7.32 $2.2M −297,500 −$2.2M
XENE, Xenon Pharmaceuticals 0.49% Exit 0 $40.15 $2.1M −53,400 −$2.1M
Akero Therapeutics 0.44% Exit 0 $47.48 $1.9M −40,500 −$1.9M
Immuneering 0.14% Exit 0 $7.00 $636K −90,900 −$636K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2025 Q3. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 45 $624M +41.2% 13F-HR 8/14/2026 000179182726000005
2026 Q1 45 $494M — new holds 5/28/2026 000179182726000004
2026 Q1 46 $442M +27.4% 13F-HR 5/13/2026 000179182726000003
2025 Q4 39 $347M −21.0% 13F-HR 2/13/2026 000179182726000002
2025 Q3 43 $439M −12.5% 13F-HR 11/14/2025 000179182725000008
2025 Q2 56 $502M −4.4% 13F-HR 8/14/2025 000179182725000007
2025 Q1 67 $525M −48.4% 13F-HR 5/15/2025 000179182725000005
2024 Q4 63 $1B −48.1% 13F-HR 2/14/2025 000179182725000002
2024 Q3 81 $2B −16.7% 13F-HR 11/14/2024 000179182724000011
2024 Q2 85 $2.4B −24.1% 13F-HR 8/14/2024 000179182724000007
2024 Q1 90 $3.1B +13.0% 13F-HR 5/15/2024 000179182724000004
2023 Q4 74 $2.7B +10.5% 13F-HR 2/14/2024 000179182724000002
2023 Q3 83 $2.5B −13.3% 13F-HR 11/14/2023 000179182723000006
2023 Q2 93 $2.9B −5.0% 13F-HR 8/14/2023 000179182723000004
2023 Q1 83 $3B −34.7% 13F-HR 5/15/2023 000179182723000003
2022 Q4 85 $4.6B −6.2% 13F-HR 2/14/2023 000179182723000002
2022 Q3 97 $4.9B +12.9% 13F-HR 11/14/2022 000179182722000008
2022 Q2 82 $4.4B −9.3% 13F-HR 8/15/2022 000179182722000006
2022 Q1 92 $4.8B +1.9% 13F-HR 5/16/2022 000179182722000004
2021 Q4 97 $4.7B +4.5% 13F-HR 2/14/2022 000179182722000002
2021 Q3 105 $4.5B — 13F-HR 11/15/2021 000179182721000006

About

Avidity Partners Management LP

21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Avidity Partners Management LP
Notable person
David Witzke
Location
Dallas, TX
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf